We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $36.15 as of December 15th.
[caption id="attachment_522188" align="aligncenter" width="750"]Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its investment thesis centered on obesity, diabetes, and NASH. Positioned...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.